Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study-Reference-Cited by-同舟云学术

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study

Published:2021-03-15 Issue:3 Volume:24 Page:852-859
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Palumbo Carlotta^ORCID,Antonelli Alessandro,Triggiani Luca,Dalla Volta Alberto^ORCID,Maffezzoni Filippo,Zamboni Stefania,Borghetti Paolo^ORCID,Rinaudo Luca,Valcamonico Francesca,Maroldi Roberto^ORCID,Magrini Stefano Maria,Simeone Claudio,Berruti Alfredo,Francavilla Simone,Furlan Maria,Gheza Alberto,Veccia Alessandro,Guerini Andrea,

Funder

Ferring

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-021-00345-0.pdf

Reference34 articles.

1. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol. 2020;77:508–47.

2. O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33:1243–51.

3. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96.